← Back to Search

Palliative Care for Parkinson's Disease (ACT for PD Trial)

N/A

Waitlist Available

Research Sponsored by University of Calgary

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up every 3 months for 2 years

Awards & highlights

ACT for PD Trial Summary

This trial examines how palliative care improves quality of life and reduces burden for those living with Parkinson's and their caregivers.

Who is the study for?

This trial is for people aged 20-100 with Parkinson's Disease or similar disorders (MSA, CBD, PSP, LBD) who need palliative care but aren't in immediate urgent need of it. It excludes those already receiving palliative/hospice care, have metastatic cancer or severe cognitive impairment.Check my eligibility

What is being tested?

The study tests the impact of multidisciplinary palliative care on quality of life and other factors for patients with parkinsonism and their caregivers. Participants will receive this specialized care and answer questions about their experiences.See study design

What are the potential side effects?

Since the intervention involves non-medical supportive services rather than drugs, traditional side effects are not expected; however, emotional or psychological distress may occur as sensitive topics are discussed.

ACT for PD Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ every 3 months for 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~every 3 months for 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and every 3 months for 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Viral Load result

Changes in Health Care Utilization survey

Alzheimer's Disease

Secondary outcome measures

Parkinson Disease

Mental disorders

Semi-structured Qualitative Interview to receive Patient and Care Partner recommendations

ACT for PD Trial Design

1Treatment groups

Experimental Treatment

Group I: Palliative careExperimental Treatment1 Intervention

Participants will receive palliative care.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Palliative care

2018

Completed Phase 3

~420

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of CalgaryLead Sponsor

791 Previous Clinical Trials

868,634 Total Patients Enrolled

Media Library

Palliative care Clinical Trial Eligibility Overview. Trial Name: NCT05599659 — N/A

Parkinson's Disease Research Study Groups: Palliative care

Parkinson's Disease Clinical Trial 2023: Palliative care Highlights & Side Effects. Trial Name: NCT05599659 — N/A

Palliative care 2023 Treatment Timeline for Medical Study. Trial Name: NCT05599659 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there a cutoff age for enrollment in this experiment?

"Applicants hoping to participate in this medical trial must be between the ages of 20 and 100. Additionally, there are 38 trials for those under 18 and 515 additional ones available to people aged 65 or older."

Answered by AI

Are new participants being welcomed into the experiment?

"As referenced on clinicaltrials.gov, the recruitment phase for this trial has been completed. Originally posted November 4th 2022 and last modified October 28th 2022, it is not presently in search of candidates; however, there are 522 other medical studies that remain active in recruiting at present."

Answered by AI

Do I satisfy the prerequisites for participation in this medical experiment?

"A cohort of 100 individuals dealing with Parkinson's disease, ranging in age from 20 to 100 years old, are eligible for enrollment. In addition, these patients must have been diagnosed with a related PDRD (Multiple System Atrophy/ Corticobasal Degeneration/ Progressive Supranuclear Palsy/ Lewy Body Dementia) and demonstrate moderate-to-high palliative needs based on the PC NAT assessment tool."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

The Calgary Movement Disorders Advanced Care Pilot Program

Veronica Bruno 2022. "The Calgary Movement Disorders Advanced Care Pilot Program". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05599659.